Dr. Gia Landry discusses her clinical experience including the clinical utility of performing HCC surveillance using the Fujifilm HCC Biomarkers, AFP-L3 and DCP.
Dr. Giogio Roccaro discusses her clinical experience including the clinical utility of performing HCC surveillance using the Fujifilm HCC Biomarkers, AFP-L3 and DCP.
This session will review the phases of biomarker validation, present the status and data for (protein and liquid biopsy) biomarkers, and discuss ongoing biomarker studies.
Dr. Charlton, Professor of Medicine University of Chicago discussed “Case Based HCC Screening and Surveillance” for CLDF (Chorionic Liver Disease Foundation).
Hepatocellular Carcinoma (HCC) Risk Factors and Surveillance: Enhance Risk Stratification with AFP-L3% and DCP Ju Dong Yang, MD, MS, Staff Physician, Karsh Division of Gastroenterology and Hepatology Cedars Sinai Medical Center 18-Nov-2020
Contents:
– HCC Surveillance Improves Patient Outcome
– How to Use AFP-L3 and DCP as Risk Biomarkers?
– What is AFP-L3?
– What is DCP?
– Biomarker Elevations Before Diagnosis
– Combined Use of AFP-L3 and DCP
– How to Order AFP-L3 and DCP?
Contents:
– Intended Use
– Clinical Utility
– How to Order
– Laboratory Test Codes
– Reimbursement Codes
Contents:
– AFP-L3 and DCP HCC Risk Assessment
– Clinical Significance:
– How to Order
– Reimbursement Codes
Contents:
Proposed Algorithm for Surveillance of Hepatocellular Carcinoma
Published in Gastroenterology and Hepatology Volume 10, Issue 2 February 2014
Contents:
A regular surveillance program for patients at risk for development of Hepatocellular Carcinoma (HCC) is recommended by clinical practice guidelines worldwide.
Contents:
Contents:
– Intended Use
– Summary and explanation of the test
– Principle of the method
– Reagents
And more
Contents:
– Intended Use
– Summary and explanation of the test
– Principle of the method
– Reagents
And more